SURVIVAL-TIME MODELS FOR ANALYZING DRUG-COMBINATION TREATMENTS

被引：0
|
作者：
KUBLER, J
SCHUMACHER, M
机构：
[1] Department of Statistics, University of Dortmund, Dortmund, D-4600
[2] Institute of Medical Biometry and Informatics, University of Freiburg, Freiburg, D-7800
来源：
STATISTICS IN MEDICINE | 1990年 / 9卷 / 12期
关键词：
D O I：
10.1002/sim.4780091216
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Several relative risk models for survival time data in drug combination therapy are derived and their properties are discussed. The main intention of this paper is to clarify the differences among the models in order to help to choose the appropriate one in a given situation. The models are motivated by discussing their relation to well‐known physiological concepts. In an example of two‐drug treatment the models are compared with each other. For this chemotherapy animal survival study, dose‐risk surfaces are fitted and optimal drug combinations are estimated. Methods for checking the model assumptions are mentioned. Copyright © 1990 John Wiley & Sons, Ltd.
引用
收藏
页码：1527 / 1539
页数：13
相关论文
共 50 条
  • [41] Survival-time distribution for inelastic collapse
    Phys Rev E., 5 pt A (R4721):
  • [42] SURVIVAL-TIME IN CYSTINOSIS - A COLLABORATIVE STUDY
    GRETZ, N
    MANZ, F
    AUGUSTIN, R
    BARRAT, TM
    BENDERGOTZE, C
    BRANDIS, M
    BREMER, HJ
    BRODEHL, J
    BROYER, M
    BULLA, M
    CALLIS, L
    CHANTLER, C
    DIEKMANN, L
    DILLON, MJ
    EGLI, F
    EHRICH, JHH
    ENDRES, W
    FANCONI, A
    FELDHOFF, C
    GEISERT, J
    GEKLE, D
    GESCHOLLBAUER, B
    GROTE, K
    GRUTTNER, R
    HAGGE, W
    HAYCOCK, CB
    HENNEMANN, H
    KLARE, B
    LEUPOLD, D
    LOHR, H
    MICHALK, D
    OLIVEIRA, A
    OTT, F
    PISTOR, K
    RAU, J
    SCHARER, K
    SCHINDERA, F
    SCHMIDT, H
    SCHULTEWISSERMANN, H
    VERRIERJONES, K
    WEBER, HP
    WILLENBOCKEL, U
    WOLF, H
    PROCEEDINGS OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION, 1982, 19 : 582 - 589
  • [43] CLINICAL INVESTIGATIONS ON THE EFFECTIVENESS OF THE DRUG-COMBINATION PROPRANOLOL DIISOPROPYLAMINDICHLORACETAT IN HYPERTENSIVES
    SCHOLZE, J
    FRILLE, J
    LINSS, G
    SCHOLZ, D
    BUDER, HW
    PRECHT, K
    FISCHER, I
    DEUTSCHE GESUNDHEITSWESEN-ZEITSCHRIFT FUR KLINISCHE MEDIZIN, 1983, 38 (25): : 963 - 967
  • [44] CURRENT SURGERY DRUG-COMBINATION TREATMENT OF DIABETIC GANGRENE OF THE FOOT
    LANGE, E
    INFECTION, 1991, 19 : S351 - S354
  • [45] Escalation with overdose control for phase I drug-combination trials
    Shi, Yun
    Yin, Guosheng
    STATISTICS IN MEDICINE, 2013, 32 (25) : 4400 - 4412
  • [46] A UNIQUE APPLICATION OF THE GRADE CRITERIA: DRUG-COMBINATION ASSOCIATED AKI
    Rivosecchi, Ryan
    Dasta, Joseph
    Kellum, John
    Kane-Gill, Sandra
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [47] DRUG-COMBINATION STUDIES WITH GINGHAOSU (ARTEMISININE) AGAINST RODENT MALARIA
    CHAWIRA, AN
    ROBINSON, BL
    WARHURST, DC
    PETERS, W
    JOURNAL OF PROTOZOOLOGY, 1984, 31 (04): : A47 - A47
  • [48] Nonparametric overdose control for dose finding in drug-combination trials
    Lam, Chi Kin
    Lin, Ruitao
    Yin, Guosheng
    TRIALS, 2017, 18
  • [49] ANTIHYPERTENSIVE ACTION OF DRUG-COMBINATION - TIMOLOL, HYDRALAZINE, HYDROCHLOROTHIAZIDE AND TRIAMTERENE
    PORSTI, P
    JALONEN, K
    RYYSY, L
    TOIVONEN, T
    VIHERKOSKI, M
    ANNALS OF CLINICAL RESEARCH, 1981, 13 (01): : 6 - 10
  • [50] Dynamic ordering design for dose finding in drug-combination trials
    Zhang, Teng
    Yang, Zhao
    Yin, Guosheng
    PHARMACEUTICAL STATISTICS, 2021, 20 (02) : 348 - 361
12345